AbbVie has initiated a clinical trial to evaluate the safety and efficacy of ABBV-706 in approximately 531 adults with relapsed/refractory small cell lung cancer (SCLC) across 175 sites globally. The trial compares ABBV-706 against standard of care treatments, which include topotecan, lurbinectedin,

ClinicalAugust 6, 2026

ABBV-706 and Atezolizumab Trial for Small Cell Lung Cancer Initiated

A clinical trial is evaluating the safety and efficacy of ABBV-706 in combination with atezolizumab versus standard of care in SCLC.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts

No catalysts indexed for this entity yet.

Indications

Small Cell Lung Cancer →

Therapeutic areas

Oncology →

Small Cell Lung Cancer →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.